Acer Therapeutics has been granted a patent for crystalline forms of emetine dihydrochloride, with processes of manufacture and methods of use. The patent claims a specific crystalline form of Compound I dihydrochloride. GlobalData’s report on Acer Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Acer Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Acer Therapeutics, Cancer immunotherapy was a key innovation area identified from patents. Acer Therapeutics's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Crystalline form of emetine dihydrochloride

Source: United States Patent and Trademark Office (USPTO). Credit: Acer Therapeutics Inc

A recently granted patent (Publication Number: US11884663B2) discloses a crystalline form of Compound I dihydrochloride, characterized by specific X-ray powder diffractograms. The patent claims various forms of the crystalline compound, each with distinct peaks in their diffractograms, such as Form 2, Form 4, Form 5, and Form 6. Additionally, the patent covers pharmaceutical compositions containing the crystalline form of Compound I dihydrochloride along with a pharmaceutically acceptable carrier, and optionally, other therapeutic agents like antiparasitic agents, antibiotics, antiviral agents, or agents for controlling a cytokine storm.

Furthermore, the patent describes methods of treating viral infections, including Flavivirus infections like Zika virus, West Nile virus, and dengue virus, by administering the crystalline form of Compound I dihydrochloride. The methods also extend to treating viral infections caused by various viruses such as Ebola virus, HIV-1, influenza A virus, and coronaviruses like SARS-COV-2. Notably, the patent specifies treating diseases caused by SARS-COV-2, including COVID-19, in subjects who do not require hospitalization, with the crystalline form of Compound I dihydrochloride, potentially mitigating severe symptoms of Cytokine Release Syndrome. The patent's comprehensive coverage of crystalline forms, pharmaceutical compositions, and treatment methods underscores its potential significance in addressing a range of viral infections and diseases.

To know more about GlobalData’s detailed insights on Acer Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies